Global Health Investment Fund (GHIF)
VC Fund
New York, United States
Global Health Investment Fund (GHIF) is a VC fund in New York focused on Health Care and Biotechnology. The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 43%
- Fund size:
- $108M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Global Health Investment Fund (GHIF) invests in
Stages Global Health Investment Fund (GHIF) invests in
Countries Global Health Investment Fund (GHIF) invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $7.5M–$19M
- Series C
- $4.5M–$14M
- Venture - Series Unknown
- $3.5M–$25M
Investment Focus
Industry
- Health Care 12 (57%)
- Biotechnology 10 (48%)
- Medical Device 7 (33%)
- Medical 6 (29%)
- Biopharma 2 (10%)
Stage
- Series B 3 (14%)
- Series C 3 (14%)
- Venture - Series Unknown 3 (14%)
- Seed 2 (10%)
- Series A 2 (10%)
Country
- United States 9 (43%)
- India 1 (5%)
- Austria 1 (5%)
- Belgium 1 (5%)
- Australia 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Curt LaBelle
Managing Partner & President
|
Managing Partner & President | Total investments: 7 | Find email | |
Kabeer Aziz
Associate
|
Associate | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally. | $32M / Series A / Sep 30, 2022 | ||
| Monod Bio is a life sciences company developing biosensors for protein and other analyte detection. Its biosensor platform combines binding, transduction, and amplification to detect a range of target molecules. It utilizes recent advances in computational protein engineering to create highly modular bio-sensing nano switches that stimulate rapid,sensitive, and inexpensive analytical assays.Monod Bio was founded in 2021 and is headquartered in Seattle, Washington. | $25M / Seed / Aug 15, 2022 | ||
| Endpoint Health is a precision immunology company that is breaking the efficacy barrier of traditional pharma's “one-size-fits-all” drug development strategy by developing precision therapies with outsized efficacy potential in autoimmune and inflammatory conditions. They’re accomplishing this by leveraging OMNAI, their proprietary AI-poweredpatient discovery platform, to identify and match high-potential therapies to the patients most likely to respond. | $52M / Series A / Jun 02, 2022 | ||
| Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk’s first product, the EyeArt AI Eye Screening System, is the most extensively validated AItechnology for autonomous detection of diabetic retinopathy. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease. | $6.2M / Venture - Series Unknown / Jul 20, 2021 | ||
| Alydia Health is a medical device company working toward a solution to postpartum hemorrhage (PPH), the number one cause of maternal death. Their single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. They are devoted to improving the lives of womenaround the world. | $13.9M / Series C / Jul 30, 2020 | ||
| 'Digital Health', 'Health Tech', Virtual Care', 'Digital Rehab', Remote Patient Monitoring' | $1.5M / Seed / Dec 10, 2019 | ||
| Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing andacquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies. | $44.1M / Series D / Sep 18, 2019 | ||
| Alydia Health is a medical device company working toward a solution to postpartum hemorrhage (PPH), the number one cause of maternal death. Their single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. They are devoted to improving the lives of womenaround the world. | $10.3M / Series B / Aug 28, 2018 | ||
| Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%.Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based onsingle-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture. | $18.7M / Series B / Jul 16, 2018 | ||
| Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing andacquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies. | $12M / Series C / Jan 03, 2018 | ||
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Global Health Investment Fund (GHIF) invest in?
Global Health Investment Fund (GHIF) invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series C stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Global Health Investment Fund (GHIF)'s check size?
Global Health Investment Fund (GHIF) typically joins rounds of $7.5M–$19M at Series B, $4.5M–$14M at Series C and $3.5M–$25M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Global Health Investment Fund (GHIF) participates in.
How do I contact Global Health Investment Fund (GHIF)?
Public channels for Global Health Investment Fund (GHIF) include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Global Health Investment Fund (GHIF)?
The team at Global Health Investment Fund (GHIF) includes Curt LaBelle (Managing Partner & President) and Kabeer Aziz (Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
